BioCentury | Mar 9, 2015
Finance

Can AbbVie Imbruv on this?

...a mid-single digit royalty stream on worldwide Imbruvica sales when it bought the drug's originator, Celera Corp....
...an SEC filing, Pharmacyclics has paid $28.4 million in royalties, including $27.4 million last year. Celera...
...a 2007 SEC filing, Celera sold the shares for about $3.1 million. Pharmacyclics also paid Celera...
BioCentury | Nov 13, 2014
Company News

Precision Therapeutics recaps, now Helomics

...formerly CEO of SuperNova Diagnostics Inc. (Germantown, Md.) and veteran of Abbott Laboratories (NYSE:ABT) and Celera...
BioCentury | Sep 22, 2014
Clinical News

Odanacatib: Phase III data

...the double-blind extension of the Phase III trial (see BioCentury, Feb. 4, 2013). Merck and Celera Corp....
BioCentury | Aug 19, 2013
Finance

Jumping on the gravy train

...2011 acquisition of Celera Corp. (see BioCentury, July 29) . Pharmacyclics Inc. (NASDAQ:PCYC) acquired ibrutinib from Celera...
BioCentury | Aug 19, 2013
Company News

Quest Diagnostics, Royalty Pharma deal

...million for the stake. Quest gained the ibrutinib royalty rights through its 2011 acquisition of Celera Corp....
...or about $344 million net of cash. Pharmacyclics Inc. (NASDAQ:PCYC, Sunnyvale Calif.) acquired ibrutinib from Celera...
BioCentury | Aug 12, 2013
Top Story

Aisling, Clarus acquire stake in ibrutinib royalty stream

...million for the stake. Quest gained the ibrutinib royalty rights through its 2011 acquisition of Celera Corp....
...$670.8 million or about $344 million net of cash. Pharmacyclics Inc. (NASDAQ:PCYC) acquired ibrutinib from Celera...
BioCentury | Jul 29, 2013
Finance

Ibrutinib force

...lymphoma (SLL). In 2006, Pharmacyclics acquired then-preclinical ibrutinib and two other small molecule programs from Celera Corp....
...as the latter offloaded its therapeutics portfolio to concentrate on molecular diagnostics and biomarker discovery. Celera...
...2011, Quest acquired Celera for $670.8 million, or $344 million net of cash. Quest wanted Celera's...
BioCentury | Jul 22, 2013
Finance

Highlights of weekly biotech stock moves

...ibrutinib royalty rights through its 2011 acquisition of Celera Corp. Pharmacyclics Inc. (NASDAQ:PCYC) acquired ibrutinib from Celera...
BioCentury | Jul 22, 2013
Company News

Quest Diagnostics, Royalty Pharma deal

...diagnostic information services business. Quest gained the ibrutinib royalty rights through its 2011 acquisition of Celera Corp....
...or about $344 million net of cash. Pharmacyclics Inc. (NASDAQ:PCYC, Sunnyvale, Calif.) acquired ibrutinib from Celera...
...see BioCentury, April 17, 2006 & May 23, 2011). Quest retains royalty rights to other Celera...
BioCentury | Jul 19, 2013
Top Story

Royalty Pharma acquires ibrutinib royalties

...$485 million in cash. Quest gained the ibrutinib royalty rights through its 2011 acquisition of Celera Corp....
...$670.8 million or about $344 million net of cash. Pharmacyclics Inc. (NASDAQ:PCYC) acquired ibrutinib from Celera...
Items per page:
1 - 10 of 575
BioCentury | Mar 9, 2015
Finance

Can AbbVie Imbruv on this?

...a mid-single digit royalty stream on worldwide Imbruvica sales when it bought the drug's originator, Celera Corp....
...an SEC filing, Pharmacyclics has paid $28.4 million in royalties, including $27.4 million last year. Celera...
...a 2007 SEC filing, Celera sold the shares for about $3.1 million. Pharmacyclics also paid Celera...
BioCentury | Nov 13, 2014
Company News

Precision Therapeutics recaps, now Helomics

...formerly CEO of SuperNova Diagnostics Inc. (Germantown, Md.) and veteran of Abbott Laboratories (NYSE:ABT) and Celera...
BioCentury | Sep 22, 2014
Clinical News

Odanacatib: Phase III data

...the double-blind extension of the Phase III trial (see BioCentury, Feb. 4, 2013). Merck and Celera Corp....
BioCentury | Aug 19, 2013
Finance

Jumping on the gravy train

...2011 acquisition of Celera Corp. (see BioCentury, July 29) . Pharmacyclics Inc. (NASDAQ:PCYC) acquired ibrutinib from Celera...
BioCentury | Aug 19, 2013
Company News

Quest Diagnostics, Royalty Pharma deal

...million for the stake. Quest gained the ibrutinib royalty rights through its 2011 acquisition of Celera Corp....
...or about $344 million net of cash. Pharmacyclics Inc. (NASDAQ:PCYC, Sunnyvale Calif.) acquired ibrutinib from Celera...
BioCentury | Aug 12, 2013
Top Story

Aisling, Clarus acquire stake in ibrutinib royalty stream

...million for the stake. Quest gained the ibrutinib royalty rights through its 2011 acquisition of Celera Corp....
...$670.8 million or about $344 million net of cash. Pharmacyclics Inc. (NASDAQ:PCYC) acquired ibrutinib from Celera...
BioCentury | Jul 29, 2013
Finance

Ibrutinib force

...lymphoma (SLL). In 2006, Pharmacyclics acquired then-preclinical ibrutinib and two other small molecule programs from Celera Corp....
...as the latter offloaded its therapeutics portfolio to concentrate on molecular diagnostics and biomarker discovery. Celera...
...2011, Quest acquired Celera for $670.8 million, or $344 million net of cash. Quest wanted Celera's...
BioCentury | Jul 22, 2013
Finance

Highlights of weekly biotech stock moves

...ibrutinib royalty rights through its 2011 acquisition of Celera Corp. Pharmacyclics Inc. (NASDAQ:PCYC) acquired ibrutinib from Celera...
BioCentury | Jul 22, 2013
Company News

Quest Diagnostics, Royalty Pharma deal

...diagnostic information services business. Quest gained the ibrutinib royalty rights through its 2011 acquisition of Celera Corp....
...or about $344 million net of cash. Pharmacyclics Inc. (NASDAQ:PCYC, Sunnyvale, Calif.) acquired ibrutinib from Celera...
...see BioCentury, April 17, 2006 & May 23, 2011). Quest retains royalty rights to other Celera...
BioCentury | Jul 19, 2013
Top Story

Royalty Pharma acquires ibrutinib royalties

...$485 million in cash. Quest gained the ibrutinib royalty rights through its 2011 acquisition of Celera Corp....
...$670.8 million or about $344 million net of cash. Pharmacyclics Inc. (NASDAQ:PCYC) acquired ibrutinib from Celera...
Items per page:
1 - 10 of 575